DefinitionThis section has been translated automatically.
A genetically engineered biopharmaceutical consisting of 60 amino acids for the treatment of hereditary angioedema, which belongs to the group of so-called "Kunitz domain peptides" and is effective as an inhibitor of the enzyme kallikrein. In a clinical study (EDEMA3) on 36 patients with hereditary angioedema, Ecallantid performed better than placebo.
Pharmacodynamics (Effect)This section has been translated automatically.
As a selective inhibitor of the enzyme kallikrein, Ecallantid inhibits the production of the bradykinin responsible for swelling. Ecallantide intervenes in the kallikrein-kinin pathway at a later stage than the C1 esterase inhibitor.
You might also be interested in
Field of application/useThis section has been translated automatically.
Hereditary angioedema; ecallantide is a selective inhibitor of the enzyme kallikrein, the drug thus inhibits the production of the bradykinin responsible for the swelling. Ecallantide intervenes in the kallikrein-kinin pathway at a later stage than the C1 esterase inhibitor.
Undesirable effectsThis section has been translated automatically.
4% of patients react with anaphylactic reactions to the active substance; nausea, fatigue, headaches, diarrhoea are also observed at ADRs. Respiratory infections, fever, vomiting, itching and upper abdominal pain occurred in > 5% of patients.
PreparationsThis section has been translated automatically.
Calbitor (on the US market, but not on the European market)
LiteratureThis section has been translated automatically.
- Krome S (2010) therapy is making progress. Nude Dermatol 37:5
- Schneider L et al (2007) Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol 120:416-422
Prof. Dr. med. Peter Altmeyer